Specialties

Is there an ideal approach to screen and diagnose children and adolescents for prediabetes and diabetes?

Study shows that breastfeeding can provide diabetes inhibiting effects for over three years.

This review examines the differing arguments recent studies have made regarding blood pressure goals and cardiovascular risk. 

CREDENCE trial shows that canagliflozin, an SGLT2 inhibitor, lowers the risk of cardiovascular and renal events in patients with T2DM, regardless of prior history of heart failure. 

Sexual health questionnaires can be used as an early detection tool for men's CVD, coronary heart disease, stroke, and T2D.  

Are the mortality and cardiovascular benefits of SGLT-2 inhibitors limited to patients with type 2 diabetes who have established cardiovascular disease and renal disease?

Long-term diabetes may lead to signs of cognitive decline in Latino patients as early as middle age.

Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1RAs create an additive effect for increased anti-inflammation and vascular protection.

The FDA has approved empagliflozin Breakthrough therapy for patients with heart failure with preserved ejection fraction (HFpEF).

GLP-1 receptor agonists are a pharmacologic treatment of type 2 diabetes with potential cardiorenal benefits.